EASL Roundup: Bris­tol-My­ers and NGM post a pos­i­tive look at PhII NASH da­ta; Gen­fit de­tails PhI­II de­lay

Over the week­end some of the prospec­tive play­ers in the NASH field had a chance to roll out new da­ta on their con­tenders for the field at the an­nu­al EASL meet­ing. We were treat­ed to some in­trigu­ing ear­ly- and mid-stage da­ta on liv­er fat lev­els that could be im­por­tant fur­ther down the R&D road. And a top late-stage play­er spot­light­ed a de­lay that could set it be­hind ri­vals in the field.

Bill Berkrot at Reuters did a great deep dive on NASH, a big mar­ket dis­ease that could be worth tens of bil­lions of dol­lars every year. NASH and fat­ty liv­er dis­ease are the hall­mark of an in­creas­ing­ly obese, seden­tary glob­al pop­u­la­tion. Ul­ti­mate­ly, the dis­ease could lead to liv­er trans­plants, though there is a lot left to be learned about dis­ease pro­gres­sion and risk.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.